Visualizing the Acute Effects of Vascular-Targeted Therapy In Vivo Using Intravital Microscopy and Magnetic Resonance Imaging: Correlation with Endothelial Apoptosis, Cytokine Induction, and Treatment Outcome  by Seshadri, Mukund et al.
Visualizing the Acute Effects of Vascular-Targeted Therapy In Vivo
Using Intravital Microscopy and Magnetic Resonance Imaging:
Correlation with Endothelial Apoptosis, Cytokine Induction,
and Treatment Outcome1
Mukund Seshadri*,y, Joseph A. Spernyak*, Patricia G. Maier y, Richard T. Cheney z,
Richard Mazurchuk* and David A. Bellnier y
*Preclinical Imaging Resources, Department of Cancer Biology, Roswell Park Cancer Institute, Buffalo, NY, USA;
yPhotodynamic Therapy Center, Department of Cell Stress Biology, Roswell Park Cancer Institute, Buffalo, NY,
USA; zDepartment of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
Abstract
The acute effects of the vascular-disrupting agent
5,6-dimethylxanthenone-4-acetic acid (DMXAA) were
investigated in vivo using intravital microscopy (IVM)
and magnetic resonance imaging (MRI). Changes in
vascular permeability and blood flow of syngeneic
CT-26 murine colon adenocarcinomas were assessed
at 4 and 24 hours after DMXAA treatment (30 mg/kg,
i.p.) and correlated with induction of tumor necrosis
factor-A (TNF-A), endothelial damage [CD31/terminal
deoxynucleotidyl transferase (TdT)], and treatment
outcome. Intravital imaging revealed a marked in-
crease in vascular permeability 4 hours after treatment,
consistent with increases in intratumoral mRNA and
protein levels of TNF-A. Parallel contrast-enhanced
MRI studies showed a f 4-fold increase in longitu-
dinal relaxation rates (#R1), indicative of increased
contrast agent accumulation within the tumor. Dual-
immunostained tumor sections (CD31/TdT) revealed
evidence of endothelial apoptosis at this time point.
Twenty-four hours after treatment, extensive hemor-
rhage and complete disruption of vascular architecture
were observed with IVM, along with a significant re-
duction in #R1 and virtual absence of CD31 immuno-
staining. DMXAA-induced tumor vascular damage
resulted in significant long-term (60-day) cures com-
pared to untreated controls. Multimodality imaging
approaches are useful in visualizing the effects of anti-
vascular therapy in vivo. Such approaches allow cross
validation and correlation of findings with underlying
molecular changes contributing to treatment outcome.
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Introduction
The growth and development of most solid tumors beyond a
few millimeters are contingent on the existence of a func-
tioning vascular network [1]. The vascular architecture of
tumors is characterized by immature blood vessels with com-
plex branching patterns and irregular geometries that contribute
to spatial and temporal variations in blood flow within the tumor
[2]. Tumor-associated endothelial cells are abnormally shaped,
with loose intercellular connections and focal openings that re-
sult in enhanced permeability, compared to normal tissues
[3]. These characteristics contribute to metastatic spread
and genetic instabilities within the growing tumor that often
have a detrimental effect on therapy [4,5]. However, structural
and functional differences between normal and tumor vessels
have also allowed the development of targeted therapeutics
that selectively destroys the tumor vasculature [6]. These
vascular-disrupting agents (VDAs) target the endothelial cells
of tumors [7] and are, therefore, not associated with multidrug
resistance—a characteristic associated with poor clinical prog-
nosis with chemotherapy.
The VDA 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is
a small molecule cytokine inducer that is currently undergoing
phase II clinical evaluation2 in the United States in combination
with chemotherapeutic agents such as docetaxel [7]. Because
VDAs such as DMXAA differ from traditional anticancer cyto-
toxics in their mechanism of action, they do not always result
in significant changes in tumor size [7,8]. Therefore, the present
clinical paradigm of monitoring tumor shrinkage may not be a
sensitive-enough measure of the true efficacy of these agents.
Abbreviations: VDA, vascular-disrupting agent; DMXAA, 5,6-dimethylxanthenone-4-acetic
acid; TNF-a, tumor necrosis factor-a; MRI, magnetic resonance imaging; IVM, intravital
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Furthermore, volume change is a nonspecific biomarker that
provides little or no information early on during the course of
treatment. It is, therefore, essential to identify and develop
early biomarkers that serve as reliable predictors of thera-
peutic outcome. Imaging-based approaches have proven
extremely useful in this regard as they provide early tumor-
specific information following treatment well before macro-
scopic changes in tumor volume become evident.
We have previously demonstrated the usefulness of
contrast-enhanced magnetic resonance imaging (MRI) in
evaluating the response of human tumor xenografts to
DMXAA [9]. The ability of MRI to provide whole-body infor-
mation with high temporal and spatial resolution in a non-
invasive manner is particularly beneficial as it allows serial
monitoring of tumor response to therapy, both in preclinical
model systems and in clinical settings. However, a single
imaging methodology or assay may not adequately reflect
the entire spectrum of events that contribute to tumor growth
or response to therapy [10]. Multimodality functional imag-
ing approaches, however, would allow a more comprehen-
sive evaluation of tumor response to VDAs such as DMXAA.
The utilization of such approaches would also provide com-
plementary information that can be cross-validated and
correlated with underlying molecular mechanisms that con-
tribute to eventual treatment outcome.
In this study, we used two advanced imaging techniques,
intravital microscopy (IVM) and contrast-enhanced MRI, to
visualize and quantitate acute changes in the vascular func-
tion of CT-26 murine colon adenocarcinomas following the
administration of a single dose of DMXAA. To a large extent,
the antivascular–antitumor effects of DMXAA are related to
the in situ production of the cytokine tumor necrosis factor-a
(TNF-a) [11]. However, recent studies have shown that
DMXAA results in a variety of pharmacodynamic effects
ranging from direct effects on the vascular endothelium to
macrophage activation and natural killer cell activity [12,13].
Therefore, in addition to IVM and MRI, the antivascular–
antitumor activity of DMXAA was assessed by: 1) dual
immunohistochemical staining of tumor sections for pan en-
dothelial cell adhesion molecule (PECAM; CD31) and
terminal deoxynucleotidyl transferase (TdT) for detecting en-
dothelial apoptosis; 2) measuring intratumoral mRNA and
protein levels of TNF-a in control and DMXAA-treated animals
using polymerase chain reaction (PCR) and enzyme-linked
immunosorbent assay (ELISA), respectively; and 3) monitor-
ing long-term (60-day) tumor growth following treatment.
Materials and Methods
Tumor Model System
All experimental studies were carried out in the CT-26 mu-
rine colon adenocarcinomamodel [14] implanted in pathogen-
free syngeneic BALB/c-AnNCr mice (Jackson Laboratory,
Bar Harbor, ME). Animals were housed in microisolator
cages in a laminar flow unit within the animal facility at Roswell
Park Cancer Institute (Buffalo, NY) and fed food and water ad
libitum. For all studies except IVM, 8- to 10-week-old female
mice were inoculated subcutaneously with 1  106 CT-26
tumor cells harvested from exponentially growing cultures
and used for experimentation f 7 to 8 days after inocula-
tion, when tumors had reached a diameter of 6 to 7 mm.
For IVM studies, f 5  105 tumor cells were injected within
dorsal skinfold window preparations, and studies were car-
ried out 10 to 12 days postimplantation. All studies were
performed in accordance with Institutional Animal Care and
Use Committee–approved protocols.
DMXAA
DMXAA powder was provided by Gordon Rewcastle
(University of Auckland, Auckland, New Zealand) and freshly
formulated in 5% sodium bicarbonate before intraperitoneal
injection at a dose of 30 mg/kg.
IVM
To visualize changes in vascular architecture and function
following DMXAA treatment, intravital imaging based on the
dorsal skinfold window preparation was used [15,16]. Briefly,
8- to 10-week-old female BALB/c mice (n = 5) were anesthe-
tized with a ketamine/xylazine mixture (10:1) at a dose of
1.0 ml/100 mg. Each mouse was shaved from the neck
down to the tail with a clipper and then depilated with Nair
(Church & Dwight Co., Inc, Princeton, NJ); the skin was
disinfected with hexidine and alcohol. The midline of each
animal was then marked with a sterile skin marker, and a ‘‘C’’
clamp was sutured onto the skin of the animal. A circular skin
flap f 10 mm in diameter was then raised on the dorsal
skinfold, leaving all vessels on the opposite side of the skin-
fold intact. A small amount of saline was periodically injected
to keep the surface moist. The two frames of the window
chamber were then mounted and secured onto the skin with
screws and sutures. Topical antibiotic was applied onto the
edges of the wound to prevent subsequent dermal infection.
Tumor cells (5 105) were then injected into the fascia within
the preparation, and the chamber was filled with saline. A
glass cover slip was placed over the window preparation, and
a retaining ring was applied with pliers on top of the cover slip.
Following recovery, mice were transferred onto laminar flow
barrier cages containing food and water and placed in a
humidified temperature-controlled incubator (32jC). Tumor
growth within the window chambers was monitored every
24 hours, and experiments were carried outf 10 to 12 days
postimplantation, during which tumors grew tof 3 to 4 mm,
with a well-vascularized network visible within the window
chambers. Bright field images were digitally acquired using a
surgical microscope with a mounted color camera (Endure
Medical, Inc., Cumming, GA) before treatment and 4 and
24 hours after DMXAA administration.
Contrast-Enhanced MRI
All studies were performed using a 4.7-T/33-cm horizontal
bore MR scanner (GE NMR Instruments, Fremont, CA)
incorporating AVANCE digital electronics (Bruker Medical,
Billerica, MA), a removable gradient coil insert (G060; Bruker
Medical) generating a maximum field strength of 950 mT/m,
and a custom-designed radiofrequency transreceiver coil.
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Tumor-bearing mice (n = 7) were anesthetized using 4%
isoflurane (Abbott Laboratories, Chicago, IL), secured in a
mouse coil chamber, and positioned on the scanner. Anes-
thesia was maintained at 1% to 2% during imaging, and a
circulating water bath maintained at 37jC was used to
keep the animals warm inside the magnet. Preliminary
noncontrast-enhanced images were acquired before the
administration of the contrast agent to obtain regional
T1 measurements. The macromolecular MR contrast agent
MacroGd (PharmaIn, Buffalo Grove, IL) was administered
manually through tail vein injection at a dose of 0.1 mmol/kg
Gd. The agent is a long-circulating gadolinium-containing
macromolecule that consists of a monomethoxy ether of
polyethylene glycol attached to poly-L-lysine–Gd-DTPA
[17,18]. Following administration of the contrast agent, a
second set of scans was acquired, and longitudinal relaxa-
tion rates (R1) were calculated using a saturation recovery
fast spin-echo sequence with the following: effective time of
echo period (TEeff) = 10 milliseconds; repetition time (TR) =
250 to 6000 milliseconds; field of view (FOV) = 32  32 mm;
slice thickness = 1 mm; matrix size = 128  96; number of
averages = 3. In addition, whole-body magnetic resonance
angiography (MRA) was performed using a 3D spoiled gra-
dient recalled echo scan (matrix size = 192  128  128;
FOV = 48  32  32 mm; TE = 3 milliseconds; TR = 15 milli-
seconds; flip angle = 25j). Following pretreatment acquisi-
tions, animals were divided into treatment (n = 4) and control
groups (n = 3), and DMXAA (30mg/kg, i.p.) was administered
to the mice in the treatment group. The animals were imaged
4 and 24 hours after treatment, and the change in longi-
tudinal relaxation rates (DR1) was calculated and analyzed
for statistically significant differences between the control
and treatment groups.
Image processing and analysis were carried out using
commercially available software (Analyze PC, Version 5.00;
Biomedical Imaging Resource, Mayo Clinic, Rochester, MN).
Regions of interest (ROI) of tumors, kidneys, and muscle
tissues were manually drawn on the images and object
maps of the ROI constructed. The longitudinal relaxation rate
(R1 = 1/T1) for each ROI was computed using MATLAB
(Version 7.0; Math Works, Inc., Natick, MA), and source
codes were developed by RPCI Preclinical Imaging Re-
source (Buffalo, NY). To calculate DMXAA-induced changes
in vascular function, DR1 was calculated by subtracting
postcontrast R1 values calculated immediately after contrast
agent administration from those obtained 4 and 24 hours
after contrast agent administration in both control and
DMXAA-treated tumors.
Cytokine Measurements
Determination of mRNA and protein levels of TNF-a in
CT-26 tumors was performed using reverse transcription
(RT) PCR and ELISA, respectively. At different times after
DMXAA treatment, tumors were harvested and frozen for
processing. Total RNAwas extracted from tumors using RNA
STAT-60 (Tel-Test, Inc., Friendswood, TX). First-strand syn-
thesis was performed using a first-strand cDNA synthesis kit
(K1612; Fermentas, Inc., Hanover, MD) with 2 mg of total
RNA. PCR was performed using Platium Taq DNA polymer-
ase (InVitrogen Corporation, Carlsbad, CA) for 35 cycles.
PCR products were then electrophoresed in 2% agarose
in the presence of ethidium bromide. For determination of
protein concentrations, tumor tissues were homogenized in
cell lysis buffer [CellLytic MTand Protease Inhibitor cocktail;
Sigma, St. Louis, MO (400:1)]. Supernatants were isolated,
and samples containing 40 mg of protein, as determined by
Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA),
were analyzed for TNF-a expression using an ELISA kit
(Quantikine; R&D Systems, Minneapolis, MN) specific for
the cytokine. The assays were performed in duplicate on
samples isolated from three to four mice for each time point.
Immunohistochemical Analyses
At different times after DMXAA treatment, tumors were
harvested and immediately placed in Tris-buffered zinc fixative
[0.1 M Tris–HCl buffer (pH 7.4) containing 3.2 mM calcium
acetate, 22.8 mM zinc acetate, and 36.7 mM zinc chloride]
for 18 hours. The samples were then transferred to 70%
ethanol, dehydrated, and embedded in paraffin. After conven-
tional deparaffinization and endogenous peroxidase quench-
ing, 5-mm-thick sections were stained for the PECAM CD31,
as described previously [9]. Slides were counterstained
with Harris hematoxylin (Poly Scientific, Bayshore, NY). TdT-
mediated nick end labeling was used to detect apoptosis in
tumor sections using the Apoptag plus Peroxidase in situ
detection kit (Chemicon International, Inc., Temecula, CA).
Assessment of Tumor Response
Following treatment, the dimensions of subcutaneous
tumors were measured with calipers every 1 to 3 days, and
tumor volumes were calculated using the formula: V = 0.52
(L  W 2), where L is the longest axis of the tumor and W is
perpendicular to the long axis. Animals were monitored until
tumors had reached a volume of 400mm3, at which time they
were humanely sacrificed. Regrowing tumors reached the
400-mm3 volume typically within 8 to 10 days. Animals were
considered cured if they remained tumor-free for at least
60 days after treatment. The median time to reach 400 mm3,
along with 95% confidence intervals, was estimated for
control and DMXAA-treated tumors using the method of
Kaplan and Meier [19].
Statistical Analysis
All measured values are reported as the mean ± standard
error of themean. Five animals (control group, two; treatment
group, three) were used for IVM studies. For immunohisto-
chemistry and cytokine measurements, at least three mice
each were used for the control and treatment groups. Seven
animals (control group, three; treatment group, four) were
used for MRI. Sixteen animals (control group, 10; treatment
group, 6) were used for tumor response studies. Two-tailed
t-test was used for comparing individual treatment groups
with controls. P = .05 was considered statistically signifi-
cant. The survival curves of untreated control and DMXAA-
treated animals were analyzed using log-rank test to test the
null hypothesis that the curves were identical. All statistical
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calculations and analyses were performed using Graph Pad
Prism (Version 4.00; San Diego, CA).
Results
Before imaging the antivascular effects of DMXAA in vivo,
intravital imaging was performed to observe differences in
vascular architecture between tumor and normal tissues. As
shown in Figure 1, the skin of a nontumorous BALB/c mouse
exhibited a highly organized vascular network with well-
defined branching patterns (control ). To observe changes in
vessel geometry during the early stages of tumor growth, serial
intravital images were acquired at different times after the
injection of CT-26 tumors (Figure 1). By day 4 after implanta-
tion of tumor cells in the window chambers, changes in the
geometry of host vessels were visible. The vessels appeared
dilated in several areas (yellow arrows), with some having a
high degree of tortuosity compared to day 1. These changes
became more obvious on day 6, after implantation with sig-
nificant vasodilation and increased tortuosity seen within the
window chambers (arrows). In comparison, the vessels of
nontumorous mice did not show such changes in vessel size
or tortuosity, highlighting the fact that these changes were
tumor-specific and associated with the induction of angio-
genesis [16]. On completion of baseline image acquisitions,
mice were injected with DMXAA (30 mg/kg, i.p.), and images
wereacquired 4 and24hours after treatment (n =3). As shown
in Figure 2, 4 hours after DMXAA treatment, significant vas-
cular leakage was seen within the window chamber, with signs
of hemorrhage (upper panel ). Twenty-four hours after treat-
ment, complete loss of vessel integrity, with severe hemor-
rhage visible in intravital images, was indicative of DMXAA-
induced vascular damage. Inspection of the skin around the
window chamber and at a distant site (mouse ear; not shown)
revealed no such change in vascular integrity or function, con-
firming the tumor-selective antivascular activity of DMXAA.
To correlate the intravital findings of tumor response
to DMXAA, contrast-enhanced MRI was performed in a
parallel study, using a separate cohort of animals (n = 7).
Whole-body MRA was performed to visualize changes in
tumor vascular function following DMXAA (Figure 2, middle
panel ). Consistent with intravital findings, the MRA of
DMXAA-treated tumors (n = 4) revealed a marked increase
in vascular permeability at 4 hours, compared to untreated
controls (n = 3). Change in enhancement following the
administration of the macromolecular MR contrast agent
was visualized and quantitated by measuring the change in
longitudinal relaxation rate DR1 (1/T1) in tumor and kidney
tissues. Kidneys were used as a surrogate measure of
contrast agent concentration in the blood. The calculated
temporal change in DR1 (tumor/blood) showed a f 7-fold
increase (P < .01) in DMXAA-treated animals (0.708 ± 0.109)
compared to untreated controls (0.129 ± 0.05) at this time
point (Figure 3). Subsequently, 24 hours after treatment,
whereas DR1 values continued to increase in untreated con-
trol tumors, mice treated with DMXAA showed a decrease
close to baseline levels reflective of DMXAA-induced reduc-
tion in vascular perfusion.
Immunohistochemical staining of CT-26 tumor sections
for the PECAM along with TdT (CD31/TdT) was performed to
Figure 1. Intravital microscopic images of normal and tumor-associated vasculature in a BALB/c mouse dorsal skin window chamber. Representative images of
normal host cutaneous vasculature (control) and vasculature associated with a growing CT-26 tumor within dorsal skinfold window chambers implanted in BALB/c
mice. Serial intravital images were acquired following the injection of CT-26 tumor cells to monitor changes in vessel geometry and architecture with tumor growth.
Arrows indicate corresponding areas in the images acquired at different times (days 1, 4, and 6) after tumor implantation that showed significant host vessel dilation
and increased tortuosity.
Multimodality Imaging Vascular-Targeted Therapy In Vivo Seshadri et al. 131
Neoplasia . Vol. 9, No. 2, 2007
correlate with changes in image-based parameters of vas-
cular function (Figure 2, bottom panel ). Tumor sections
obtained from untreated control mice showed well-defined
clusters of endothelial cellswith crispCD31staining (Figure 2,
left ). Strong TdT reactivity (arrows) was seen in CD31+ blood
vessels in CT-26 tumor sections 4 hours after treatment, in-
dicative of endothelial apoptosis (center). Twenty-four hours
after treatment, extensive TdT reactivity with virtual ab-
sence of identifiable CD31 reactive blood vessels was seen
(Figure 2, lower panel, right ). Regions of preexisting vessels
could be identified by a faint reddish blush (rectangles) in
tumor sections at this time point.
One of the major biological intermediates believed to
be responsible for the antivascular–antitumor activity of
DMXAA is TNF-a [11]. To determine whether changes in
vascular permeability corresponded with induction of TNF-a,
RT-PCR was performed on tumors at different times follow-
ing treatment (Figure 4A). Untreated control CT-26 tumors
did not show any upregulation of mRNA for TNF-a. In com-
parison, increased mRNA levels were detected in DMXAA-
treated tumors between 1 and 2 hours after treatment. To
further quantify intratumoral cytokine levels in control and
DMXAA-treated tumors, ELISA was performed on tumor tis-
sue extracts at 1, 2, and 4 hours after treatment (Figure 4B).
No significant change (P > .5) in TNF-a levels was seen in
DMXAA-treated tumors 1 hour after treatment (6.50 ± 0.866)
compared to untreated controls (8.25 ± 0.75). Consistent with
RT-PCR data, a marked increase (f 20-fold) in intratumoral
concentrations of TNF-a was detected at 2 hours after treat-
ment (285.8 ± 37.76; P < .001 vs control). TNF-a levels mea-
sured in tumors 4 hours after DMXAA treatment showed a
further increase (443.5 ± 48.52; P = .0001) compared to
untreated controls. The difference in TNF-a levels between
the 2-hour and the 4-hour time points was also statistically
significant (P < .05).
Finally, to determine the effects of DMXAA-based anti-
vascular therapy on long-term treatment outcome, tumor-
bearing mice were injected with DMXAA (30 mg/kg) and
monitored for a period of 60 days following treatment for
tumor regrowth. Survival curves based on the Kaplan-Meier
method were generated for untreated controls and DMXAA-
treated animals. As seen in Figure 5, DMXAA resulted in
significant tumor control, withf 80% of the mice remaining
tumor-free at 60 days (P < .001).
Discussion
The essential role of the vasculature in malignant progres-
sion, combined with the differential characteristics of tumor
and normal vessels, has led to the development of thera-
peutics that either disrupt existing tumor vessels (VDAs) or
inhibit new vessel formation (antiangiogenics) [1,8]. These
Figure 2. IVM, contrast-enhanced MRI, and immunohistochemical assessment of CT-26 tumor response to DMXAA. Intravital (upper panel) and contrast-
enhanced MR (middle panel) images of CT-26 colon adenocarcinomas acquired before treatment (preRx), 4 hours after treatment with DMXAA (4 h), and 24 hours
after treatment with DMXAA (24 h). Imaging-based changes in vascular function correlated with immunohistochemical analysis (CD31/TdT) of tumor sections
(lower panel). Four hours after treatment, endothelial apoptosis (arrows) was visible in DMXAA-treated tumors. Ghost outlines of vessels were seen at 24 hours
after treatment (rectangles). Representative images of individual mice from each methodology have been shown.
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biological therapies that selectively target tumors differ fun-
damentally in their mechanism(s) of action from conventional
cancer chemotherapies and do not always result in tumor
shrinkage following treatment [7,8]. This is particularly impor-
tant as anatomical imaging-based approaches that have
traditionally been used to assess tumor response to chemo-
therapy or radiation therapy rely on volumetric change and
may not be beneficial in the evaluation of vascular-targeted
therapies. Furthermore, it is widely recognized that molec-
ular alterations within the tumor occur much before macro-
scopic changes in gross tumor volume can be detected. It is,
therefore, essential to use functional imaging techniques that
provide early quantitative end points reflective of underlying
biological change.
The purpose of this study was to assess the antivascular
effects of the VDA DMXAA in vivo using a multimodality
imaging approach and to correlate imaging-based changes
in vascular function with underlying molecular changes
that contributed to its antitumor effect. Using two advanced
imaging techniques, IVM and contrast-enhanced MRI, acute
vascular changes following DMXAA administration were
evaluated in a murine carcinoma model. Alterations in tumor
vascular permeability and perfusion following treatment
correlated with endothelial apoptosis, intratumoral levels of
TNF-a, and long-term tumor response.
Intravital imaging based on the dorsal skinfold window
chamber technique is an extremely useful method that allows
visualization of tumor vessels in real time at high resolution
[16]. The ability of IVM to allow a serial assessment of tumors
Figure 3. Temporal change in the longitudinal MR relaxation rate (DR1 tumor/
blood) of control and DMXAA-treated CT-26 tumors implanted in BALB/c
mice. Graph shows the change in T1 relaxation rates (DR1) over time of
untreated control tumors (squares) and tumors treated with 30 mg/kg DMXAA
following administration of the macromolecular contrast agent. Significant
differences in DR1 values (**P < .01; two-tailed t-test) were seen 4 hours after
DMXAA treatment (n = 3) compared to untreated controls (n = 3).
Figure 4. Induction of TNF-a at different times after DMXAA treatment. BALB/c
mice bearing subcutaneous CT-26 tumors were injected with DMXAA and, at
different times after treatment, tumors were excised for the determination of
mRNA (A) and protein levels of TNF-a (B) using PCR and ELISA, respectively.
Statistical analyses (two-tailed t-test) revealed significant differences be-
tween control and treatment groups at 2 and 4 hours after treatment
(***P < .001). At least three to four mice were used for each time point.
Figure 5. Long-term treatment outcome following antivascular therapy.
BALB/c mice bearing subcutaneous CT-26 tumors were injected with 30 mg/
kg DMXAA, and tumor growth was monitored for 60 days after treatment.
Kaplan-Meier survival curves of untreated controls (n = 10) and DMXAA-
treated animals (n = 6). A significant difference in survival was seen between
control and treatment groups (**P < .01; log-rank test).
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is particularly useful in studying molecular events asso-
ciated with angiogenesis and the response of tumors to anti-
angiogenic or antivascular therapies [16,20]. In the present
study, vascularization of CT-26 tumors within the dorsal skin-
fold window chamber was clearly visualized, with changes
in vascular architecture visible as early as 2 days after im-
plantation (Figure 1). Intravital imaging showed evidence of
altered permeability 4 hours after DMXAA administration.
This is in agreement with a previous study by Zhao et al.
[21], in which, using Evans blue extravasation, it was dem-
onstrated that the major mechanism of action of DMXAAwas
increase in tumor vascular permeability. Twenty-four hours
after treatment, complete destruction of tumor vascular ar-
chitecture was seen with IVM, consistent with previous
preclinical reports of reduction in vascular perfusion and on-
set of necrosis at this time point [21,22]. Intravital imaging
offers the ability to directly visualize angiogenesis and tumor
vascular response to treatment in a live animal; however, due
to its invasive nature and the requirement of a specialized
surgical preparation of tissues, it cannot be readily translated
into the clinical setting. To validate IVM findings, parallel
studies were carried out using MRI.
Contrast-enhanced MRI is a noninvasive imaging tech-
nique that provides functional images of the tumor vasculature
in animal models and is routinely used in humans [23].
Although resolution of individual tumor vessels is difficult with
MRI, the technique offers excellent tissue contrast and pro-
vides whole-body renderings that allow the simultaneous
evaluation of tumor and normal tissues. Several preclinical
and clinical studies have used dynamic contrast-enhanced
(DCE) MRI to assess the response of tumors to VDAs such
as DMXAA and CA4P, with limited success [22,24]. A ma-
jority of these DCE-MRI studies have been performed using
small molecule MR contrast agents, typically Gd-DTPA, to
estimate parameters of tumor vascular permeability (K trans)
and blood flow (area under the curve) following treatment.
However, reduction in these parameters has only been in-
consistently observed in preclinical studies, particularly with
DMXAA [24,25]. Even in the phase I clinical trial of DMXAA,
DCE-MRI parameters did not reveal a dependable dose re-
sponse in patients, questioning the true clinical utility of the
technique [25]. In comparison, several studies have reported
the usefulness of macromolecular MR contrast agents for
measuring changes in the permeability and perfusion of tu-
mors in response to inhibitors of angiogenesis [18,26]. In this
study, we used one such macromolecular contrast agent
that exhibits a longer intravascular distribution compared to
Gd-DTPA [17]. The long half-life and low first-pass elimina-
tion of the agent allowed themonitoring of changes in vascular
permeability/perfusion with a single injection. The agent has
been shown to be nonimmunogenic, capable of producing
superior quality images with high contrast-to-noise ratio, and
useful in the assessment of antiangiogenic therapies [17,18].
The selective destruction of the tumor vasculature leading
to the secondary ischemic necrosis of tumor cells is the
fundamental basis of the antitumor activity of DMXAA [13].
The development of DMXAA was based on the selective
induction of TNF-a in situ [11]. TNF-a is a pleiotropic cytokine
that is produced mainly by activated cells of monocyte/mac-
rophage lineage [27]. TNF-a has been shown to cause the
necrosis of tumors in experimental animals, primarily through
toxic effects on the tumor vasculature [28]. The antivascular
effects ofDMXAAare, therefore, believed to be, at least in part,
related to the effects of TNF-a [11]. The induction of TNF-a
following DMXAA treatment has been studied extensively in
murine tumors and human tumor xenografts [11,29]. In our
study, intratumoral measurements of TNF-a showed a strong
correlation to observed changes in vascular permeability
(Figure 4). This is not surprising as the effects of TNF-a on
the vascular endothelium have been previously shown to
include changes in the shape and motility of endothelial cells,
upregulation of adhesion molecules such as E-selectin, and
the recruitment and activation of leukocytes [28,30,31]. These,
in turn, result in the initiation of vascular injury, loss of vascular
tone, and increase in endothelial permeability.
Although the major mechanism of action of DMXAA is be-
lieved to be the induction of TNF-a in situ, recent studies have
shown evidence of direct drug toxicity to the vascular endo-
thelium [12]. Reductions in tumor blood flow have been
observed early on after the administration of DMXAA, much
before changes in plasma or tumor TNF-a levels can be
measured [12]. This has been attributed to direct drug-
induced endothelial damage that results in a cascade of
events ranging from exposure of basement membrane to
platelet activation to serotonin release and changes in vas-
cular permeability [12,13]. In a previous study by Ching et al.
[12], induction of endothelial cell apoptosis has been ob-
served within 30 minutes of the administration of 25 mg/kg
DMXAA to Colon-38 tumor-bearing mice without any detect-
able apoptosis of tumor cells. In the same study, endothelial
cell apoptosis was also reported to have been observed in a
breast carcinoma biopsy from a patient in the phase I trial
of DMXAA. In the murine carcinomamodel used in our study,
a similar evidence of endothelial apoptosis was seen 30 min-
utes after DMXAA (data not shown). In our study, tumor
sections dual-stained for CD31/TdT showed clear evidence
of endothelial apoptosis at 4 hours (Figure 2), indicating that
the increased vascular permeability seen at this time point is
a cumulative effect of both direct drug effects on the endo-
thelium and indirect effects mediated by cytokine induction.
Twenty-four hours after DMXAA treatment, CT-26 tumor
sections showed a virtual absence of CD31 reactivity indic-
ative of significant vascular damage, further highlighting the
relationship between endothelial damage and reduction in
vascular perfusion. Taken together, the results of our study
show that DMXAA resulted in an early dramatic increase in
vascular permeability that is visible after a few hours of
treatment, consistent with endothelial damage and increased
cytokine induction. These changes subsequently led to com-
plete disruption of vascular architecture, reduction in blood
flow, and a high percentage of tumor cures.
In conclusion, multimodality imaging of the vasculature
with a high degree of correlation is feasible in vivo and is
a useful tool in the assessment of antivascular and anti-
angiogenic therapies. Although a number of functional imag-
ing techniques are currently being studied or are in progress,
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there has been little validation of imaging methodologies
with accepted molecular surrogates of disease process or
treatment outcome. In this report, we have demonstrated
the usefulness of a multimodality approach using two com-
plementary advanced imaging techniques, IVM and MRI,
to understand and characterize response to antivascular
therapy in an experimental tumor model. Although quantita-
tive estimates of changes in vessel geometry (lumen size or
diameter) were not performed, to the best of our knowledge,
this is the first study wherein direct visualization of the re-
sponse of individual tumor vessels to DMXAA using IVM has
been reported. Studies aiming to visualize and quantitate
functional changes in tumor vessels (vascular resistance and
red blood cell velocity) in response to DMXAA treatment are
currently being planned in our laboratory. One limitation of our
study was the use of separate cohorts of animals for IVM
and MRI studies. Although the window chambers used in
the study are nonmagnetic, preliminary MRI studies car-
ried out on animals implanted with these titanium-based
window chambers revealed significant artifacts at the tissue–
chamber interface, which prevented the accurate visualiza-
tion of corresponding areas on the same group of animals
with both techniques.We are currently exploring the potential
utility of an MR-compatible window chamber that allows the
simultaneous assessment of tumor vascular response to
therapy using MRI and IVM within the same animal. Prelim-
inary studies have revealed encouraging results with good
correlation between the two techniques [32]. Studies aiming
to develop image-based algorithms that will allow coregis-
tration of functional images from multiple imaging techniques
are also ongoing in our laboratory. We believe that the suc-
cessful development of these coregistration algorithms will
enable the utilization of complementary imaging techniques
to make meaningful comparisons between different results
obtained and to provide insights into the mechanism(s) of
action of vascular-targeted therapies in vivo.
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